Eminent Fortis, Max, Medanta, Sir Ganga Ram Hospital Surgeons launch da Vinci Surgical Robot on wheels

USA and Vattikuti Foundation are showcasing the technology to surgeons and hospital administrators in 20 Indian cities over the next 90 days.

“da Vinci Surgical System enables surgeons to operate minimally invasively through a few small incisions or the belly button from a nearby ergonomic console. As a result of this technology, da Vinci allows surgeons to operate with enhanced vision, precision and control,” says Gopal Chakravarthy, CEO, Vattikuti Technologies.
Eminent surgeons such as Dr Arvind Kumar, Director, Institute of Robotic Surgery at Sir Ganga Ram Hospital; Dr Gagan Gautam, Head of Urologic Oncology & Robotic Surgery, Max Institute of Cancer Care; Dr N.P. Gupta, Chairman, Kidney & Urology Institute, Medanta Medicity, Gurgaon; Dr Rama Joshi, Director, Gynae Oncology Fortis Memorial Research Institute, Gurgaon endorsed and highlighted the benefits of robotic surgery in areas of their specialisation while flagging off the surgical robot on a vehicle here last week.
According to them robotic surgery causes less trauma with surgeon being in full control of the entire procedure.

The da Vinci Surgical Robot on the special mobile vehicle simulates an operating room lounge as it gives exposure to doctors in smaller towns.

The Vattikuti Technologies and Vattikuti Foundation have helped expand Robotic Surgery to 51 da Vinci Robot installations, manned by 275 trained robotic surgeons in 47 hospitals in 20 cities in a short period.

In 2016, over 750,000 procedures were performed worldwide using over 4000 da Vinci robotic surgical systems world-wide. The da Vinci system has brought about a paradigm shift by making it possible to have almost all complex procedures done with minimal access. Over 4 million da Vinci procedures have been carried out so far.
Since 2011 Vattikuti Technologies has partnered with several hospitals in drawing a roadmap for success of the robotic program as well as supporting training of surgeons besides ensuring high uptime for the system through its trained clinical support and service team.
Large corporate hospitals such as Apollo, Aster, Fortis, HCG, Max, Medanta; Government hospitals such as AIIMS, Army Research & Referral Hospital, Delhi State Cancer Institute,  PGI, Chandigarh, Kidwai Memorial Institute of Oncology; and Trust hospitals such as Tata Memorial, Mumbai, Amrita Institute, Kochi, Sir Ganga Ram Hospital, Rajiv Gandhi Cancer Institute are using the da Vinci Surgical Robots.

Source:https://www.indiablooms.com/ibns_new/health-details/H/2788/eminent-fortis-max-medanta-sir-ganga-ram-hospital-surgeons-launch-da-vinci-surgical-robot-on-wheels.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more